OBJECTIVES: To assess the impact of oral antidiabetics agents on weight change in Type 2 Diabetes Mellitus (T2DM) patients age 65 years and older. METHODS: An electronic medical record, General Electric Centricity research database, containing the ambulatory health records of US patients was used to conduct a historical cohort study of the T2DM elderly patients identified by ICD-9 codes, OAD prescription or both. Six months of continuous OAD monotherapy activity was required, and study period included 395 days pre/210 days post from the index date. Two BMI/weight readings were mandated, at baseline, and follow up. Data were analyzed using ANOVA with Tukey test to correct for multiple comparisons.  RESULTS: A total of 2720 patients with a primary diagnosis of T2DM were included in the study. The overall mean age was 72.7 years. Statistical significant differences between users of different OADs at baseline were found for diastolic blood pressure (p=0.0009), and age (p<0.001) The most prescribed OAD medications were metformin (58.9%), glipizide (14.52%) and glimepiride (7.76%).The overall mean change in A1C level was -0.92 (p<0.001) units and statistically significant differences were found when compared Metformin/Glipizide (mean difference 0.51320, 95% CI 0.06411-0.96230). The overall mean baseline BMI among all of the OAD groups was 29.08 kg/m². Significant differences in BMI units change were found for meglitinide users, (-1.27), metformin users (-1.06), and the sulfonylureas (-0.14).  An average of 3.97 lb weight loss for all of the OAD groups was found. Major weight loss was found in the Metformin group (-6.41lb), and the Sulfonylureas group reported the least weight loss (-0.89lb). CONCLUSIONS: An association was found between the OAD use and change in weight measured by BMI and raw weight in elderly T2DM patients in a real-world setting. The likelihood of weight loss in OAD users was somewhat consistent with the literature.